{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:13:54Z","timestamp":1787984034486,"version":"build-2784847793"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03488-w","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T07:11:47Z","timestamp":1738307507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registries"],"prefix":"10.1186","volume":"27","author":[{"given":"Adrian","family":"Ciurea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seraphina","family":"Kissling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"G\u00f6tschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lykke Midtb\u00f8ll","family":"\u00d8rnbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Horskj\u00e6r","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1lint","family":"Tam\u00e1si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Glintborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Gitte","family":"Loft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almut","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Br\u00e4m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pavelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Z\u00e1vada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao Madruga","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Gudbjornsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olafur","family":"Palsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vappu","family":"Rantalaiho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritva","family":"Peltomaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalin","family":"Codreanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Mogosan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth T.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Macfarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Castrejon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziga","family":"Rotar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Michelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan K.","family":"Wallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"van der Horst-Bruinsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Micheroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ospelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"3488_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957\u201370.","journal-title":"N Engl J Med"},{"key":"3488_CR2","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391:2273\u201384.","journal-title":"Lancet"},{"key":"3488_CR3","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/S0140-6736(18)30949-8","volume":"391","author":"F Van den Bosch","year":"2018","unstructured":"Van den Bosch F, Coates L. Clinical management of psoriatic arthritis. Lancet. 2018;391:2285\u201394.","journal-title":"Lancet"},{"key":"3488_CR4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700\u201312.","journal-title":"Ann Rheum Dis"},{"key":"3488_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465\u201379.","journal-title":"Nat Rev Rheumatol"},{"key":"3488_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyat G, Ogdie A, et al. 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71:5\u201332.","journal-title":"Arthritis Rheumatol"},{"key":"3488_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41584-022-00874-5","volume":"19","author":"A Najm","year":"2023","unstructured":"Najm A, Goodyear CS, McInnes IB, et al. Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy. Nat Rev Rheumatol. 2023;19:153\u201365.","journal-title":"Nat Rev Rheumatol"},{"key":"3488_CR8","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1002\/acr.20577","volume":"63","author":"PJ Mease","year":"2011","unstructured":"Mease PJ. Measures of psoriatic arthritis. Arthritis Care Res. 2011;63:S64\u201385.","journal-title":"Arthritis Care Res"},{"key":"3488_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/ard.51.2.177","volume":"51","author":"D van der Heijde","year":"1992","unstructured":"van der Heijde D, van\u2019t Hof MA, van Riel PL, et al. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis. 1992;51:177\u201381.","journal-title":"Ann Rheum Dis"},{"key":"3488_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nrrheum.2017.96","volume":"13","author":"C Ospelt","year":"2017","unstructured":"Ospelt C, Frank-Bertoncelj M. Why location matters \u2013 site-specific factors in rheumatic diseases. Nat Rev Rheumatol. 2017;13:433\u201342.","journal-title":"Nat Rev Rheumatol"},{"key":"3488_CR11","doi-asserted-by":"publisher","first-page":"12877","DOI":"10.1073\/pnas.162488599","volume":"99","author":"HY Chang","year":"2002","unstructured":"Chang HY, Chi J-T, Dudoit S, et al. Diversity, topographic differentiation, and memory in human fibroblasts. Proc Nat Acad Sci. 2002;99:12877\u201382.","journal-title":"Proc Nat Acad Sci"},{"key":"3488_CR12","doi-asserted-by":"publisher","first-page":"14852","DOI":"10.1038\/ncomms14852","volume":"8","author":"M Frank-Bertoncelj","year":"2017","unstructured":"Frank-Bertoncelj M, Trenkmann M, Klein K, et al. Epigenetically-driven anatomical diversity of synovial fibroblasts guides joint-specific fibroblast functions. Nat Commun. 2017;8:14852.","journal-title":"Nat Commun"},{"key":"3488_CR13","doi-asserted-by":"publisher","first-page":"11849","DOI":"10.1038\/ncomms11849","volume":"7","author":"R Ai","year":"2016","unstructured":"Ai R, Hammaker D, Boyle DL, et al. Joint-specific DNA methylation and transcriptome signatures in rheumatoid arthritis identify distinct pathogenic processes. Nat Commun. 2016;7:11849.","journal-title":"Nat Commun"},{"key":"3488_CR14","doi-asserted-by":"publisher","first-page":"8172","DOI":"10.1038\/s41467-023-44053-w","volume":"14","author":"M Elhai","year":"2023","unstructured":"Elhai M, Micheroli M, Houtman M, et al. The long non-coding RNA HOTAIR contributes to joint-specific gene expression in rheumatoid arthritis. Nat Commun. 2023;14:8172.","journal-title":"Nat Commun"},{"key":"3488_CR15","doi-asserted-by":"publisher","unstructured":"Bolton C, Croft AP. All fibroblasts are equal, but some are more equal than others. Nat Rev Rheumatol. 2024. https:\/\/doi.org\/10.1038\/s41584-024-01097-6.","DOI":"10.1038\/s41584-024-01097-6"},{"key":"3488_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13075-023-03184-7","volume":"25","author":"L Linde","year":"2023","unstructured":"Linde L, \u00d8rnbjerg LM, Rasmussen SH, et al. Commonalities and differences in set-up and data collection across European spondyloarthritis registries \u2013 results from the EuroSpA collaboration. Arthritis Res Ther. 2023;25:205.","journal-title":"Arthritis Res Ther"},{"key":"3488_CR17","doi-asserted-by":"publisher","first-page":"100706","DOI":"10.1016\/j.lanepe.2023.100706","volume":"33","author":"B Michelsen","year":"2023","unstructured":"Michelsen B, \u00d8stergaard M, Nissen MJ, et al. Differences and similarities between the EULAR\/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe. Lancet Reg Health Eur. 2023;33:100706.","journal-title":"Lancet Reg Health Eur"},{"key":"3488_CR18","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1093\/rheumatology\/kez427","volume":"59","author":"CH Brahe","year":"2020","unstructured":"Brahe CH, \u00d8rnbjerg LM, Jacobsson L, et al. Retention and response rates in 14261 PsA patients starting TNF inhibitor treatment \u2013 results from 12 countries in EuroSpA. Rheumatology (Oxford). 2020;59:1640\u201350.","journal-title":"Rheumatology (Oxford)"},{"key":"3488_CR19","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/annrheumdis-2021-220097","volume":"80","author":"U Lindstr\u00f6m","year":"2021","unstructured":"Lindstr\u00f6m U, Di Giuseppe D, Delcoigne B, et al. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Ann Rheum Dis. 2021;80:1440\u20138.","journal-title":"Ann Rheum Dis"},{"key":"3488_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13075-023-03144-1","volume":"25","author":"A Ciurea","year":"2023","unstructured":"Ciurea A, Distler O, Kwok K, et al. Joint-level responses to tofacitinib and methotrexate: a post-hoc analysis of data from ORAL start. Arthritis Res Ther. 2023;25:185.","journal-title":"Arthritis Res Ther"},{"key":"3488_CR21","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.berh.2016.08.012","volume":"30","author":"M \u00d8stergaard","year":"2016","unstructured":"\u00d8stergaard M, Eder L, Christiansen SN, et al. Imaging in the diagnosis and management of peripheral psoriatic arthritis \u2013 The clinical utility of magnetic resonance imaging and ultrasonography. Best Pract Res Clin Rheumatol. 2016;30:624\u201337.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"3488_CR22","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1136\/annrheumdis-2015-208806","volume":"75","author":"B Michelsen","year":"2016","unstructured":"Michelsen B, Diamantopoulos AP, Hammer HB, et al. Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity. Ann Rheum Dis. 2016;75:2108\u201313.","journal-title":"Ann Rheum Dis"},{"key":"3488_CR23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/rheumatology\/keab384","volume":"61","author":"SK Felbo","year":"2022","unstructured":"Felbo SK, Wiell C, \u00d8stergaard M, et al. Do tender joints in active psoriatic arthritis reflect inflammation assessed by ultrasound and magnetic resonance imaging? Rheumatology (Oxford). 2022;61:723\u201333.","journal-title":"Rheumatology (Oxford)"},{"key":"3488_CR24","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1136\/ard-2022-222787","volume":"82","author":"I Gessl","year":"2023","unstructured":"Gessl I, Hana CA, Deimel T, et al. Tenderness and radiographic progression in rheumatoid arthritis and psoriatic arthritis. Ann Rheum Dis. 2023;82:344\u201350.","journal-title":"Ann Rheum Dis"},{"key":"3488_CR25","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/sjos.12291","volume":"45","author":"T Hothorn","year":"2018","unstructured":"Hothorn T, M\u00f6st L, B\u00fchlmann P. Most likely transformations Scand J Statist. 2018;45:110\u201334.","journal-title":"Most likely transformations Scand J Statist"},{"key":"3488_CR26","first-page":"398","volume":"13","author":"B Tamasi","year":"2021","unstructured":"Tamasi B, Hothorn T. tramME: Mixed-effects transformation models using template model builder. R Journal. 2021;13:398\u2013418.","journal-title":"R Journal"},{"issue":"Suppl II","key":"3488_CR27","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1136\/ard.2004.032318","volume":"64","author":"PS Helliwell","year":"2005","unstructured":"Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis. 2005;64(Suppl II):ii3\u20138.","journal-title":"Ann Rheum Dis"},{"key":"3488_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/ard.2006.054288","volume":"66","author":"PS Helliwell","year":"2007","unstructured":"Helliwell PS, Porter G, Taylor WJ, et al. Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis. Ann Rheum Dis. 2007;66:113\u20137.","journal-title":"Ann Rheum Dis"},{"key":"3488_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JMH Moll","year":"1973","unstructured":"Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55\u201378.","journal-title":"Semin Arthritis Rheum"},{"key":"3488_CR30","unstructured":"R Core Team, R. A language and environment for statistical computing. R foundation for statistical computing. Vienna, Austria; 2022 https:\/\/www.R-project.org."},{"key":"3488_CR31","doi-asserted-by":"publisher","DOI":"10.1201\/9781003097471","volume-title":"R Markdown Cookbook","author":"Y Xie","year":"2020","unstructured":"Xie Y, Dervieux C, Riederer E. R Markdown Cookbook. 1st ed. New York: Chapman and Hall\/CRC; 2020.","edition":"1"},{"key":"3488_CR32","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s10067-017-3637-2","volume":"36","author":"D Stekhoven","year":"2017","unstructured":"Stekhoven D, Scherer A, Nissen MJ, et al. Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping. Clin Rheumatol. 2017;36:2035\u201343.","journal-title":"Clin Rheumatol"},{"key":"3488_CR33","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/art.37939","volume":"65","author":"LC Coates","year":"2013","unstructured":"Coates LC, FitzGerald O, Gladman DD, et al. Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease. Arthritis Rheum. 2013;65:1504\u20139.","journal-title":"Arthritis Rheum"},{"key":"3488_CR34","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/1529-0131(200004)43:4<865::AID-ANR18>3.0.CO;2-W","volume":"43","author":"PS Helliwell","year":"2000","unstructured":"Helliwell PS, Hetthen J, Sokoll K, et al. Joint symmetry in early and late rheumatoid and psoriatic arthritis: comparison with a mathematical model. Arthritis Rheum. 2000;43:865\u201371.","journal-title":"Arthritis Rheum."},{"key":"3488_CR35","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1136\/annrheumdis-2013-203643","volume":"73","author":"P Jacques","year":"2014","unstructured":"Jacques P, Lambrecht S, Verheugen E, et al. Proof of concept\u202f: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis. 2014;73:437\u201345.","journal-title":"Ann Rheum Dis"},{"key":"3488_CR36","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1002\/art.22758","volume":"8","author":"D McGonagle","year":"2007","unstructured":"McGonagle D, Lories RJU, Tan AL, et al. The concept of a \u201csynovio-entheseal complex\u201d and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum. 2007;8:2482\u201391.","journal-title":"Arthritis Rheum"},{"key":"3488_CR37","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1136\/ard.2007.073932","volume":"67","author":"E Pattison","year":"2008","unstructured":"Pattison E, Harrison BJ, Griffiths CEM, et al. Environmental risk factors for the development of psoriatic arthritis\u202f: results from a case-control study. Ann Rheum Dis. 2008;67:672\u20136.","journal-title":"Ann Rheum Dis"},{"key":"3488_CR38","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1136\/annrheumdis-2017-212681","volume":"77","author":"I Tinazzi","year":"2018","unstructured":"Tinazzi I, McGonagle D, Aydin SZ, et al. \u201cDeep Koebner\u201d phenomenon of the flexor tendon-associated accessory pulleys as a novel factor in tenosynovitis and dactylitis in psoriatic arthritis. Ann Rheum Dis. 2018;77:922\u20135.","journal-title":"Ann Rheum Dis"},{"key":"3488_CR39","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.semarthrit.2018.06.001","volume":"48","author":"WL Zhou","year":"2019","unstructured":"Zhou WL, Chandran V, Cook R, et al. The association between occupational-related mechanical stress and radiographic damage in psoriatic arthritis. Semin Arthritis Rheum. 2019;48:638\u201343.","journal-title":"Semin Arthritis Rheum"},{"key":"3488_CR40","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1053\/sarh.2001.19957","volume":"30","author":"D Caspi","year":"2001","unstructured":"Caspi D, Flusser G, Farber I, et al. Clinical, radiological, demographic, and occupational aspects of hand osteoarthritis in the elderly. Semin Arthritis Rheum. 2001;30:321\u201331.","journal-title":"Semin Arthritis Rheum"},{"key":"3488_CR41","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1093\/rheumatology\/35.11.1106","volume":"35","author":"E Fex","year":"1996","unstructured":"Fex E, Jonsson K, Johnson U, et al. Development of radiographic damage during the first 5\u20136 year of rheumatoid arthritis. A prospective follow-up study of a Swedish cohort. Br J Rheumatol. 1996;35:1106\u201315.","journal-title":"Br J Rheumatol"},{"key":"3488_CR42","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/annrheumdis-2021-220882","volume":"81","author":"SL Heckert","year":"2022","unstructured":"Heckert SL, Bergstra SA, Matthijssen XME, et al. Joint inflammation tends to recur in the same joints during the rheumatoid arthritis disease course. Ann Rheum Dis. 2022;81:169\u201374.","journal-title":"Ann Rheum Dis"},{"key":"3488_CR43","doi-asserted-by":"publisher","first-page":"e002552","DOI":"10.1136\/rmdopen-2022-002552","volume":"9","author":"SL Heckert","year":"2023","unstructured":"Heckert SL, Bergstra SA, Goekoop-Ruiterman YPM, et al. Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment. RMD Open. 2023;9:e002552.","journal-title":"RMD Open"},{"key":"3488_CR44","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.3899\/jrheum.110677","volume":"39","author":"M Grunke","year":"2012","unstructured":"Grunke M, Witt MN, Ronneberger M, et al. Use of the 28-joint count yields significantly higher concordance between different examiners than the 66\/68-joint count. J Rheumatol. 2012;39:1334\u201340.","journal-title":"J Rheumatol"},{"key":"3488_CR45","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1136\/ard.2006.051706","volume":"65","author":"J Fransen","year":"2006","unstructured":"Fransen J, Antoni C, Mease PJ, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomized controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis. 2006;65:1373\u20138.","journal-title":"Ann Rheum Dis"},{"key":"3488_CR46","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13075-021-02534-7","volume":"23","author":"MJ Nissen","year":"2021","unstructured":"Nissen MJ, M\u00f6ller B, Ciurea A, et al. Site-specific resolution of enthesitis in patients with axial spondyloarthritis treated with tumor necrosis factor inhibitors. Arthritis Res Ther. 2021;23:165.","journal-title":"Arthritis Res Ther"},{"key":"3488_CR47","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/bjd.16081","volume":"178","author":"EA Langan","year":"2018","unstructured":"Langan EA, Griffiths CEM, Solbach W, et al. The role of the microbiome in psoriasis: moving from disease description to treatment selection? Br J Dermatol. 2018;178:1020\u20137.","journal-title":"Br J Dermatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03488-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03488-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03488-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T07:13:55Z","timestamp":1738307635000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03488-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3488"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03488-w","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"13 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the respective national data protection agencies and research ethical committees according to legal regulatory requirements in the participating countries (online supplemental table S6).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AG reports a grant from Novartis (paid to employer). AGL reports a research grant from Novartis; speaking and\/or consulting fees from Abbvie, Janssen, Eli Lilly, MSD, Novartis, Pfizer, and UCB; and being a paid instructor for Pfizer. BeG reports a grant from Novartis (paid to institution); grants from Abbvie, BMS, and Sandoz paid to the institution, outside the submitted work. BrM reports a research grant from Novartis paid to the employer (outside the submitted work); speaker fees from Novartis; grants from the Research Council of Norway to the Centre for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY). CC reports speaking and consulting fees from Abbvie, Amgen, Boehringer-Ingelheim, Ewopharma, Eli Lilly, Novartis, and Pfizer. FI reports a provision from Abbvie for article processing; consulting fees from Abbvie, Janssen, and UCB; payments or honoraria from Abbvie, Eli Lilly, Galapagos, Janssen, and UCB; support for attending meetings from Abbvie, Astra-Zeneca, Eli Lilly, Galapagos, Janssen, and UCB. GTJ reports a research grant from Amgen paid to the employer; speaker fees from Janssen. IC reports speaker and\/or consulting fees form BMS, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, MSD, Pfizer, and GSK. IvdHB reports payment for lecture from UCB and support for attending a meeting from Pfizer. JMD reports grants from the Portuguese Society of Rheumatology (RheumaPlus grant); consulting fees from Abbvie, Bial, Merck Sharp & Dohme, and Pfizer; payments or honoraria from Abbvie, Bial, Merck Sharp & Dohme, Novartis, Pfizer, and UCB; JKW reports speaking fees from Abbvie, and Amgen (paid to institution); research support from Abbvie, Amgen, Eli Lilly, Novartis, and Pfizer (unrelated to the present study and paid to institution); he acts as co-chair of the Swedish Society for Rheumatology\u2019s working group which is annually updating the Swedish treatment recommendations for axial spondyloarthritis and psoriatic arthritis. JZ reports speaking fees from Abbvie, Akord, Astra Zeneca, Celltrion, Eli Lilly, Pfizer, and Sobi; consulting fees from Abbvie, and Astra Zeneca; support for attending meetings from Abbvie, and Pfizer; participation in advisory boards for Abbvie, and Astra Zeneca. KP reports consulting fees from Abbvie, UCB, Pfizer, Eli Lilly, Celltrion, MSD, and Novartis. LM\u00d8 reports a research grant from Novartis paid to the employer. MJN reports a research grant from Novartis paid to the institution; consulting fees from Abbvie, Amgen, Eli Lilly, Janssen, Novartis, and Pfizer paid to the institution; speaking fees from Abbvie, Amgen, Eli Lilly, Janssen, Novartis, and Pfizer paid to the institution; support for attending meetings from Janssen and UCB; participation in advisory boards from Eli Lilly, Janssen, Novartis and Pfizer paid to the institution; he is a scientific member of the SCQM registry and of the EuroSpA collaboration and an ASAS-EULAR taskforce member. M\u00d8 reports grants from Abbvie, Amgen, BMS, Celgene, Eli Lilly, Merck, Novartis, and UCB, outside the submitted work; consulting fees from Abbvie, BMS, Eli Lilly, Galapagos, Gilead, Janssen, Merck, Novatis, Pfizer, and UCB; payments or honoraria from Abbvie, BMS, Eli Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Pifzer, and UCB. MLH reports consulting fees from Abbvie paid to institution; research grants from Abbvie, BMS, Eli Lilly, Lundbeck Fondation, MSD, Pfizer, Sandoz, Novartis, and Nordforsk, all paid to institution; speaking fees from Pfizer, Medac, Sandoz paid to the institution and a personal honorarium from Novartis; participation in an advisory board of Abbvie paid to the institution; being the previous chair of the steering committee of the Danish Rheumatology Quality Registers, which receive public funding from the hospital owners and from pharmaceutical companies; she co-chairs EuroSpA, which generates real-world evidence of treatment of psoriatic arthritis and axial spondyloarthritis based on secondary data and is partly funded by Novartis. MS reports consulting fees from Janssen-Cilag, Boehringer-Ingelheim, and Pfizer; payments or honoraria from BMS, Boehringer-Ingelheim, and GSK. RM reports payments or honoraria from Abbvie, Amgen, Eli Lilly, and Janssen Biotech. RP reports consulting fees from Boehringer Ingelheim and Celltrion, speaking fees from Boehringer Ingelheim, Eli Lilly, Janssen, and UCB; participation in advisory boards for Boehringer Ingelheim, Eli Lilly, and UCB. SHR reports a research grant from Novartis. SK reports a grant from Novartis (paid to employer). VR reports personal grants for the expenses of the research group from the competitive State Research Financing of the Expert Responsibility Area of Kanta-H\u00e4me Central Hospital and of Tampere University Hospital, as well as from the Wilhelm and Else Stockmann\u2019s Foundation; payments or honoraria from Abbvie, Novartis, and Viatris. ZR reports payment or honoraria from Abbvie, Amgen, AstraZeneca, Boehringer, Biogen, Eli Lilly, Janssen, Medis, MSD, Novartis, Pfizer, Roche, and Sandoz Lek; payments for expert testimony from Abbvie, Amgen, AstraZeneca, Boehringer, Biogen, Eli Lilly, Janssen, Medis, MSD, Novartis, Pfizer, Roche, and Sandoz Lek; being president of the section of rheumatology of the Slovenian Medical Association. AC, AS, BM, BT, BjG, BuM, CM, CO, GJM, OD, OP, PV, and RB declare they have no conflicts of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}